Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers

NCT ID: NCT00569777

Last Updated: 2015-03-06

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

310 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal volunteers

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergic Conjunctivitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

K-lens

etafilcon A contact lens with ketotifen.

Group Type EXPERIMENTAL

K-Lens (generic name not established) and Ketotifen

Intervention Type DEVICE

combination drug-device product: contact lens (device) and anti-allergy drug

Placebo

etafilcon A contact lens without ketotifen

Group Type PLACEBO_COMPARATOR

Placebo Lens

Intervention Type DEVICE

contact lens without drug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

K-Lens (generic name not established) and Ketotifen

combination drug-device product: contact lens (device) and anti-allergy drug

Intervention Type DEVICE

Placebo Lens

contact lens without drug

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy normal, soft contact lens wearing volunteers
* normal ocular health
* contact lens correction from +6.00 to -12.00D in each eye and astigmatism of -1.00D or less in each eye

Exclusion Criteria

* active ocular infection
* history of ocular surgery
* use of topical ophthalmic preparations (including rewetting drops)
* pregnancy or lactation
Minimum Eligible Age

8 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vistakon Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Brian Pall, OD, MS, FAAO

Role: STUDY_DIRECTOR

Johnson & Johnson Vision Care, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gardena, California, United States

Site Status

North Andover, Massachusetts, United States

Site Status

Memphis, Tennessee, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

07-003-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.